eFFECTOR Therapeutics IPO

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is eFFECTOR Therapeutics's ticker symbol?

EFTR

What is eFFECTOR Therapeutics's stock price?

0.363343 as of 3/27/23

eFFECTOR Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/24/2017 Series C $197.73MM $XXX.XX $XXX.XX
12/22/2015 Series B $141.22MM $XXX.XX $XXX.XX
5/20/2013 Series A $67.04MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about eFFECTOR Therapeutics

Forge green plus iconForge green minus icon

What is eFFECTOR Therapeutics funding to date?

eFFECTOR Therapeutics has raised $152.08MM with the following series:
$67.04MM for Series A, $141.22MM for Series B, $197.73MM for Series C, $67.04MM for Series A, $141.22MM for Series B, $197.73MM for Series C.
Forge green plus iconForge green minus icon

When was eFFECTOR Therapeutics founded?

eFFECTOR Therapeutics was founded in 2012.